PhageAtlas® – Global Interactive Map of Phage Therapy Companies

We are introducing PhageAtlas®, the result of extensive research and bibliographic work dedicated to mapping the global phage therapy and biotech ecosystem. PhageAtlas is an interactive world map showcasing companies, startups, and biotech organizations across all continents working in the field of phage therapy and related antibacterial innovations. It brings together, for the first time, a structured and centralized overview of this emerging industry. Each entity is geolocated and enriched with key information, including contact details, core projects, scientific focus, and visual identity. Users can explore the global landscape through an intelligent search system by company name, city, country, or continent. By aggregating fragmented data into a single dynamic platform, PhageAtlas provides a clear and accessible view of the international biotech ecosystem driving innovation in phage-based therapies.

0 Companies
0 Countries
0 Continents

Companies Directory

Comments

  1. Rudy Shweiler19 March 2026 at 16:12

    Honestly, its the best Phage Atlas that i have come across, great work The Phage Therapy Team !

    ReplyDelete

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more